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Abstract
This research suggests the development of a universal
protocol for prophylactic administration of Pitocin in the
third stage of labor in order to prevent postpartum
hemorrhage and decrease maternal mortality rates (MMR).
The United States MMR has increased from 16.9 per 100,000
live births in 1990 to 26.4 per 100,000 live births in 2015
(Zelop, 2018, p. 8). It is imperative that health care providers
intervene at the third stage of labor to decrease the risk of
death and complications.
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Introduction
The title question was constructed using the PICO method.
The “P” stands for the population of participants of interest
in the clinical setting; pregnant and laboring women is the
population for the purposes of this research. The “I”
represents the intervention needed for practice and for this
research project “prophylactic Pitocin administration
protocols”. Within the PICO question the “C” stands for
comparisons of interventions to determine the best
intervention for practice. In this research, the “C” stands for
no administration of Pitocin. Finally, the “O” stands for
outcomes needed for practice and ways to measure the
outcomes in practice. For the purposes of this research, “O”
represents the decreased risk of postpartum hemorrhage and
maternal deaths.

This research advises the prophylactic administration of
Pitocin in order to prevent or decrease the risk of postpartum
hemorrhages. Early intervention will decrease the MMR as
44.4% of maternal deaths occur in the 6 week time period
after delivery of the fetus. (Zelop, 2018). The health system
needs to be more proactive by “encompassing antepartum,
intrapartum, postpartum and interconception care” (Zelop,
2018, p. 11). On a global scale, an average of one woman
dies every 4 minutes as a result of postpartum hemorrhage
complications (Moncneff, 2018). A postpartum hemorrhage
is defined as a blood loss of ≥500mL in a vaginal delivery or
a blood loss of ≥1,000mL in a cesarean delivery (Perry, S.
E., et al., 2018).

Pitocin is the synthetic form of oxytocin and is used to
stimulate uterine smooth muscle to contract the uterus in
order to induce labor or to control bleeding postpartum
(Davis Drug Guide, 2020). It is a vasopressor and
antidiuretic;therefore, it is important to monitor the patient's
blood pressure throughout administration (Davis Drug
Guide, 2020).

Research suggests that the administration of prophylactic
Pitocin in the third stage of labor intravenously or
intramuscularly decreases the risk of postpartum hemorrhage
by 40% (Cássia de Oliveira & Barbosa-Davim, 2019). The
FDA (2020) recommends 40 units/ in 1,000 mL of lactated
ringer's intravenously (IV) or 10 units of Pitocin
intramuscular (IM) administration in the event that the
patient is showing signs of PPH. However, there is no
protocol for routine use in the third stage of labor and it is
often up to physician discretion. The Queensland Clinic
(2019), recommends the prophylactic administration of
Pitocin on all pts beginning at 10 international units via IM
injection for a vaginal birth and 5 international units via IV
for a cesarean section.
Table1
Medication Used for Prevention and Treatment of Postpartum
Hemorrhage

Evaluation and Analysis
In a study done that compares the blood loss and incidence of
postpartum hemorrhage (PPH), there was a control group and
an experimental group used. The control group did not
receive the routine use of prophylactic oxytocin (RUPO),
while the experimental group, or the RUPO group, did. The
study shows that “the incidence of PPH ≥ 1,000 mL was also
significantly reduced from 14.0% in the control group to
6.1% in the RUPO group, despite the women in the RUPO
group being more obese and having a longer first stage of
labor, both of which are risk factors of excessive bleeding,”
(Kuzume, Akiko, et al., para 16, 2017).
Table 2
Risk Factors of PPH: The 4 Ts

Source: (Moncrieff, 2018, p. 224).

Conclusion
Overall, this research aimed to reveal that “there is a global
concern to implement health actions that can adequately
prevent and treat the complications of PPH, which in many
cases causes maternal morbidity and mortality,” (Cássia de
Oliveira & Barbosa-Davim, 2019). Prophylactic Pitocin is
crucial in all patients in order to prevent and treat postpartum
hemorrhages. Research show that “For clinical practice,
providers might benefit from knowing 10 IU of IV bolus is a
good, safe option for women after vaginal delivery,”
(Charles, D. et al., p. 6, 2019).

Recommendations for Future Research
Figure 2
Maternal Mortality Rate

Source: (Zelop, 2019, p. 8).

Overall, there is a lack of research available addressing the
significant rise of maternal morbidity in the United States. It
is alarming that such a well developed country has such high
maternal mortality rates, Therefore, more research needs to
be done in order to provide quality and safe care of all
laboring patients. In regards to future research, there needs to
be more studies done in order to provide for all patient
populations; for example,“current clinical practice guidelines
for third stage oxytocin administration do not distinguish
between women with prior oxytocin exposure and those
without” (Bischoff, K., et al., p. 10, 2017). It’s
“recommended that hospitals establish protocols to enable an
optimal response to changes in maternal vital signs and
clinical conditions. These protocols should be tested in drills,
and systems problems that interfere with care should be fixed
through their continual refinement,” (Evesen, A., Anderson,
J., & Fontaine, P., p. 447, 2017).
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